Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Exclusion Criteria

• •Treatment with any medications and therapies not permitted during the study.
• •History of myeloproliferative disease.
• •Malignancy within 5 years at Screening with the exception of nonmelanoma skin cancer, carcinoma in situ, or prostate cancer not requiring treatment.
• •Current, or a recent clinically significant history of, uncontrolled renal, hepatic(including currently active hepatitis B virus and / or hepatitis C virus), hematologic, endocrine, pulmonary, psychiatric, or cardiac disease, assessed as potentially having an effect on study outcomes as determined by the Investigator and / or Sponsor.
• •Congenital or acquired immunosuppressive condition(s), including human immunodeficiency virus infection.
• •Clinical signs of active infection and / or fever \> 38°C during the 7 days before Day 1.
• •Clinically significant abnormalities on physical examination, ECG, or laboratory assessments, or neutropenia (defined as absolute neutrophil count \< 2.0 × 109/L) at Screening.
• •Subjects with PPP only: concurrent psoriasis vulgaris (not including scaly scalp and / or ears).
• •Subjects with HS only: \> 20 draining fistulas."